Reduced Injectable, Short-course for (E)Xpert MDR-TB [RISE trial]
(E)Xpert 耐多药结核病的短期注射减少 [RISE 试验]
基本信息
- 批准号:8732395
- 负责人:
- 金额:$ 24.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-11 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:Admission activityAdultAdverse effectsAdverse eventAftercareAminoglycosidesAudiometryBangladeshBiological AssayCaringChestClinic VisitsClinical ResearchClinical TrialsClinical Trials DesignCollaborationsCommunitiesCountryDevelopmentDiagnosisDiagnosticDiseaseDrug CombinationsDrug KineticsExposure toFailureHospital ReferralsHospitalizationHospitalsHumanInfectionInferiorInjectableInstitutesInternationalLaboratoriesManualsMeasurementMicroscopyModelingMonitorMulti-Drug ResistanceMultidrug-Resistant TuberculosisNewly DiagnosedOutcomePatientsPharmaceutical PreparationsPhasePopulationPredispositionProtocols documentationPulmonary TuberculosisRandomizedRandomized Controlled TrialsRegimenReportingResearch InfrastructureResearch InstituteResourcesRetreatmentSecureSiteSputumSwellingSymptomsSystemTanzaniaTestingTimeTreatment ProtocolsTuberculosisUniversitiesVirginiaadvanced diseasebasebed capacitycohortdata managementdosageexperiencehearing impairmentimmunosuppressedimprovedinnovationmortalitynoveloperationprogramspublic health relevancescreeningstandard of caresuccesstherapy durationtransmission processtreatment centertreatment durationtuberculosis treatment
项目摘要
PROJECT SUMMARY/ABSTRACT
Of the nearly 9 million new case of tuberculosis (TB) in 2011, it is estimated that 500,000 were
multidrug-resistant (MDR), but less than 20% were started on MDR-TB treatment. The inability to make the
diagnosis of MDR-TB in the ambulatory setting, limited bed capacity at specialized treatment centers, and
resource-intensive, prolonged treatment courses of toxic medication regimens, contribute to the failure to
initiate MDR-TB treatment which drives mortality and fuels community transmission. Fortunately rapid
diagnostics like the Xpert MTB/RIF can now detect MDR-TB in the time of a single clinic visit, and large scale
roll-out to ambulatory screening sites are underway (including at our study sites in Bangladesh and Tanzania).
Yet the swell of new, largely ambulatory, patients will further create a treatment bottleneck unless
governmental TB programs are massively expanded, or the duration of treatment regimens can be shortened
and administered outside of the hospital. The latter is most immediately achievable. To do so, we propose an
innovative approach to both minimize the necessity for prolonged hospitalization and to shorten the total
treatment duration. We will test this approach by (1) employing a regimen of optimized pharmacokinetics
based on local quantitative susceptible testing, (2) limiting the exposure to the most resource-intensive and
toxic component of the multidrug regimen, the injectable aminoglycoside, and (3) applying the regimen to an
ambulatory population with low bacterial burden. Thus, the proposed phase IIb non-inferiority trial, Reduced
Injectable, Short-course for (E)Xpert MDR-TB (RISE trial), will randomize ambulatory patients newly diagnosed
with MDR-TB by the Xpert MTB/RIF assay to the novel regimen (1 month injectable aminoglycoside, 12
months total treatment duration) or the current standard of care (6+ months injectable aminoglycoside, 20+
months total treatment duration) to compare rates of treatment success, and medication related adverse
events. This proposal leverages strong collaboration with the University of Virginia and the clinical trials
infrastructure of the Kilimanjaro Clinical Research Institute in Tanzania and the ICDDR,B in Bangladesh. The
R34 will allow critical assessment of trial design, provide support for development of a complete study protocol,
operations manual, and data management system, and securing of preliminary approvals.
项目总结/摘要
在2011年近900万新的结核病病例中,估计有50万是
多药耐药(MDR),但不到20%的人开始接受MDR-TB治疗。无法使
在门诊环境中诊断出耐多药结核病,专科治疗中心的床位有限,
资源密集型、毒性药物治疗方案疗程延长,导致未能
启动耐多药结核病治疗,这导致死亡率上升并助长社区传播。幸运的是,
像Xpert MTB/RIF这样的诊断现在可以在一次诊所就诊的时间内检测出MDR-TB,
正在向门诊筛查中心推广(包括我们在孟加拉国和坦桑尼亚的研究中心)。
然而,新的,大部分是流动的患者的膨胀将进一步造成治疗瓶颈,除非
政府结核病项目大规模扩大,或者治疗方案的持续时间可以缩短
并在医院外给药后者是最容易实现的。为此,我们提出一个
创新的方法,以尽量减少延长住院的必要性,并缩短总
治疗持续时间。我们将通过(1)采用优化的药代动力学方案
根据当地的定量易感性测试,(2)将暴露限制在资源最密集的地区,
多药方案的毒性组分,可注射的氨基糖苷类,和(3)将该方案应用于
低细菌负荷的流动人群。因此,拟定的IIb期非劣效性试验,
(E)Xpert MDR-TB短期注射剂(RISE试验)将随机分配新诊断的门诊患者
Xpert MTB/RIF检测新方案(1个月注射氨基糖苷类,12
总治疗持续时间为6个月)或当前标准治疗(6个月以上可注射氨基糖苷类,20个月以上
月总治疗持续时间),以比较治疗成功率和药物相关不良反应。
事件该提案利用了与弗吉尼亚大学和临床试验的密切合作,
坦桑尼亚的基利曼哈罗临床研究所和孟加拉国的ICDDR,B的基础设施。的
R34将允许对试验设计进行关键评估,为制定完整的研究方案提供支持,
业务手册和数据管理系统,并获得初步批准。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERIC R HOUPT其他文献
ERIC R HOUPT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERIC R HOUPT', 18)}}的其他基金
Mycobacterial Lung Diseases in Virginia: sequencing and clinical determinants of relapse and outcome
弗吉尼亚分枝杆菌肺病:复发和结果的测序和临床决定因素
- 批准号:
10543980 - 财政年份:2021
- 资助金额:
$ 24.1万 - 项目类别:
Mycobacterial Lung Diseases in Virginia: sequencing and clinical determinants of relapse and outcome
弗吉尼亚分枝杆菌肺病:复发和结果的测序和临床决定因素
- 批准号:
10321219 - 财政年份:2021
- 资助金额:
$ 24.1万 - 项目类别:
Diagnostics and Pharmacotherapy for Severe Forms of TB
严重结核病的诊断和药物治疗
- 批准号:
9127086 - 财政年份:2015
- 资助金额:
$ 24.1万 - 项目类别:
Diagnostics and Pharmacotherapy for Severe Forms of TB
严重结核病的诊断和药物治疗
- 批准号:
8819855 - 财政年份:2015
- 资助金额:
$ 24.1万 - 项目类别:
Genotyping and Pharmacokinetics in the HIV/MDR-TB epidemic of Eastern Siberia
东西伯利亚艾滋病毒/耐多药结核病流行的基因分型和药代动力学
- 批准号:
8793095 - 财政年份:2014
- 资助金额:
$ 24.1万 - 项目类别:
Genotyping and Pharmacokinetics in the HIV/MDR-TB epidemic of Eastern Siberia
东西伯利亚艾滋病毒/耐多药结核病流行的基因分型和药代动力学
- 批准号:
8605359 - 财政年份:2014
- 资助金额:
$ 24.1万 - 项目类别:
Molecular Diagnostic Tools for Patient Oriented Field Studies in Infectious Disea
用于以患者为导向的传染病现场研究的分子诊断工具
- 批准号:
8580369 - 财政年份:2013
- 资助金额:
$ 24.1万 - 项目类别:
Molecular Diagnostic Tools for Patient Oriented Field Studies in Infectious Diseases
用于以患者为导向的传染病现场研究的分子诊断工具
- 批准号:
10199920 - 财政年份:2013
- 资助金额:
$ 24.1万 - 项目类别:
Molecular Diagnostic Tools for Patient Oriented Field Studies in Infectious Diseases
用于以患者为导向的传染病现场研究的分子诊断工具
- 批准号:
10443710 - 财政年份:2013
- 资助金额:
$ 24.1万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 24.1万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 24.1万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 24.1万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 24.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 24.1万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 24.1万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 24.1万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 24.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 24.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 24.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)